

What is claimed is:

1. Fibrin/fibrinogen-binding conjugate comprising
a fibrin/fibrinogen-binding moiety,
a substance capturing moiety capable of reversibly binding to a
pharmaceutically active substance, and
a pharmaceutically active substance,
wherein said fibrin/fibrinogen-binding moiety is bound to said substance
capturing moiety.
2. The conjugate of claim 1, wherein said fibrin/fibrinogen-binding moiety is
selected from the group consisting of thrombin, fibronectin, bacterial fibrinogen
binding proteins, basic fibroblast growth factor, tissue-type plasminogen
activator, integrins, nucleic acids, VEGF₁₆₅ C-terminal domain, and moieties
derived from any member of this group.
3. The conjugate of claim 1, wherein said substance capturing moiety is an
antibody, a receptor or a part thereof which specifically recognizes said
pharmaceutically active substance.
4. The conjugate of claim 1, wherein said pharmaceutically active substance
is selected from the group consisting of antibiotics, growth factors, receptors for
tissue components, tissue adhesive substances, nucleic acids, plasma proteins,
hormones, heparinoids, wound-healing substances, and imaging agents.
5. The conjugate of claim 1, wherein said fibrin/fibrinogen-binding moiety
and said substance capturing moiety are covalently bound.
6. Fibrin/fibrinogen-binding conjugate comprising

a fibrin/fibrinogen-binding moiety and
a substance capturing moiety capable of reversibly binding to a
pharmaceutically active substance,
wherein said fibrin/fibrinogen-binding moiety is bound to said substance
capturing moiety.

7. Fibrin/fibrinogen-binding conjugate comprising
a fibrin/fibrinogen-binding moiety and
a pharmaceutically active substance,
wherein said fibrin/fibrinogen-binding moiety is bound to said pharmaceutically
active substance.
8. The conjugate of claim 7 wherein said fibrin/fibrinogen-binding moiety is
covalently bound to said pharmaceutically active substance.
9. The conjugate of claim 8 wherein said conjugate is a recombinant fusion
protein.
10. The conjugate of claim 9 wherein said fibrin/fibrinogen binding moiety
comprises the C-terminal domain of VEGF₁₆₅.
11. The conjugate of claim 8 wherein said fibrin/fibrinogen binding moiety is
selected from the group consisting of thrombin, fibronectin, bacterial fibrinogen
binding proteins, basic fibroblast growth factor, tissue-type plasminogen
activator, integrins, nucleic acids, VEGF₁₆₅ C-terminal domain, and moieties
derived from any member of this group.
12. The conjugate of claim 8 wherein said pharmaceutically active substance
is selected from the group consisting of antibiotics, growth factors, receptors' for

tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, wound-healing substances, and imaging agents

13. Kit for forming a depot for a pharmaceutically active substance comprising a tissue adhesive based on fibrinogen and
a fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance, wherein said fibrin/fibrinogen moiety is bound to said substance capturing moiety.
14. Kit according to claim 13, further comprising a component containing an agent capable of processing fibrinogen to fibrin.
15. Kit according to claim 14, wherein said component containing an agent capable of processing fibrinogen to fibrin is a thrombin preparation.
16. Kit according to claim 13, further comprising devices for administering said tissue adhesive and said conjugate to a depot site.
17. Method for producing a depot of a pharmaceutically active substance comprising
providing a fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance and a pharmaceutically active substance, wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety,
administering said conjugate at a depot site together with a fibrinogen preparation,

allowing processing of said fibrinogen to fibrin whereby a fibrin clot is formed, and
allowing binding of said conjugate to said fibrinogen within said fibrin clot.

18. Method for producing a depot of a pharmaceutically active substance comprising

providing a fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance and a pharmaceutically active substance, wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety,

administering said conjugate at a depot site together with a fibrinogen preparation,

allowing processing of said fibrinogen to fibrin whereby a fibrin clot is formed, and

allowing binding of said conjugate to said fibrin clot.

19. Method according to claim 18, wherein said processing of said fibrinogen to fibrin is performed by adding an agent capable of processing said fibrinogen to fibrin.

20. Method according to claim 19, wherein said agent is exogenous thrombin.

21. Depot for a pharmaceutically active substance comprising fibrin and a fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance and a pharmaceutically active substance, wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

22. Depot for a pharmaceutically active substance, said depot obtainable by the steps comprising:

providing a fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance and a pharmaceutically active substance, wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety,

administering said conjugate at a depot site together with a fibrinogen preparation,

allowing processing of said fibrinogen to fibrin whereby a fibrin clot is formed, and

allowing binding of said conjugate to said fibrinogen or said fibrin clot.

23. Method for treating a patient suffering from a pathological state, said pathological state being treatable with a pharmaceutically active substance, comprising administering to said patient an effective amount of a tissue adhesive based on fibrinogen and a fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety, a substance capturing moiety capable of reversibly binding to said pharmaceutically active substance and said pharmaceutically active substance, wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.